On January 31, Takeda closed an agreement with Adium Pharma (Tecnofarma) to sell the products of its gastrointestinal line commercialized in Argentina, Colombia, Ecuador, Peru, Guatemala, Costa Rica, Panama, and other countries in Central America and the Caribbean.
The transaction included the transfer of the entire inventory of manufactured products and raw materials, the commercialization authorization certificates, and the intellectual property (brands and patents) of the products Apatrix, Pantop, Zurcal, Proctyl y Tecta, among others.
In addition, the parties signed several commercial and technical agreements to ensure business continuity and a smooth transition of the business to Adium Pharma, which included a supply contract, a transition services contract, and a transition distribution contract for the next years.
Marval O'Farrell Mairal advised Takeda in this complex business from a multidisciplinary perspective throughout the transaction, covering support in the countries. The team was led by partners Miguel del Pino, Pablo García Morillo and Martín Mosteirin, together with associates María Luz Altieri, Carolina Andrea Ramírez and Lucía Poquet Vila, in-house lawyer Matias Giaccardi, and in-house advisers Diego Giraldi and Shawn Eisenberg.